Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors

乳腺作为内分泌干扰物影响的敏感终点

基本信息

项目摘要

Our research is focused on understanding the effects of environmental chemicals on mammary gland (MG) development, function, and cancer susceptibility. We have expanded this focus area in recent years to include the effect of environmental chemicals on breast cancer risk factors such as puberty timing, obesity, and lactation. The use of animal models for human disease allows us to evaluate different routes of exposure, internal dose of the test chemical, as well as a variety of effects in the rodent that are relevant to human health. During the last several years, we have produced numerous important documents that are being used in the risk regulation of brominated flame retardants (DE-71), perfluorooctanoic acid (PFOA) and atrazine (ATR). Flame retardants are currently regulated at the state level, as a federal risk assessment has not been completed yet. Our work on DE-71 in the rat are completed for now, but we have expanded our study of flame retardants in recent years to include tetrabromobisphenol A (TBBPA) and Firemaster 550. I continue to advise the ongoing NTP studies regarding the mechanisms of action of these high use and emerging flame retardants. In the female rodent offspring, the mammary gland is one of the most endocrine-sensitive end points that we have evaluated following prenatal chemical exposures. Our current studies using volatile organic chemicals (VOCs), bisphenol analogues, perfluorooctanoic acid (PFOA), TBBPA, and arsenic all demonstrate this finding. We are currently conducting studies evaluating mammary effects of arsenic in mice, human relevant VOC mixtures in rats, PFOA mechanism of action and strain differences in mice, and two BPA replacement chemicals in mice. I have also finalized my evaluation of the mammary samples from the BPA-CLARITY study. We have published the work on bisphenol analogues and mammary lesions in Environmental Health Perspectives recently and I have finished my final edits on the BPA-CLARITY manuscript, which will be submitted shortly. Numerous other manuscripts are expected from these studies in the coming year. We have made major progress on our work involving investigation of VOCs and their developmental exposure effects on the mammary gland, specifically in males. These compounds are theorized to have a role in male breast cancer diagnoses in men who were born or grew up at the Camp Lejeune military base in NC, USA. We have nearly finished dosimetry studies in the pregnant and lactating rat and her offspring in conjunction with our CDC collaborators. We have evaluated mammary gland development and carcinogen-induced mammary tumors following prenatal exposure and have prepared two manuscripts on the effects of these compounds in male and female rats. With this study and our mammary gland atlas of Harlan Sprague Dawley rats that will also be published this coming year, we have added significantly to what is known about male rodent mammary gland development, susceptibility to endocrine disruption, and carcinogen-induced mammary cancer. We are working with Melissa Troester, an epidemiologist at UNC, to document normal aging of the male and female mammary gland of mice and rats, in comparison to her human samples. She has shown that in women with breast cancer there is an interruption of the normal aging process, and by using chemically-exposed rodent tissues, we may determine which types of chemicals may predispose populations to increased breast cancer risk via that mode of action. We have published a recent study evaluating susceptibility to mammary gland hyperplasia in female mice exposed to bisphenol A (BPA), BPAF and BPS (fluorinated and sulfonated forms)in early life. These studies are all in line with NTP mission or in collaboration with other Federal agencies. Dispositon studies are in their final stages to understand the transfer of these compounds to the developing fetus and the clearance within the pregnant dam. These studies have been slowed due to low access to mass spec time in the NIEHS core facility and in NTPL. Our recent studies involving TBBPA and Firemaster are large collaborative studies where we either conducted the study for many PIs to get target tissues of interest (TBBPA) or we are providing a service of isolating and evaluating mammary tissue (Firemaster). Both of these flame retardants seem to act as endocrine disruptors, affecting multiple reproductive tissues, fat cells, and hormone levels. Several papers on these studies are forthcoming or in clearance. We have recently finished performing a blind evaluation of about 70 chemicals identified in Tox21 as activating specific endpoints thought to be linked to an obesogenic response. We are using mouse 3T3-L1 low passage cells to assess adipogenesis and lipogenesis. Gene expression and follow-up studies have begun on the chemicals identified as most interesting, either for their potential to act as a potent obesogen or because they were a false positive or negative. We are working with a team of investigators, including Kris Thayer at US EPA, and Jui-Hua Hseih in BSB,to produce a document on this concept and test other aspects of the chemical response. From the data accumulated in this group effort, we will better understand the utility and shortcomings of the Tox21 data set in predicting obesogens and may be able to develop assays to add to the high throughput methodology. This FY there has been a emergent need to evaluate the effects of uncharacterized perfluoroalkyl acids (PFAS)and related compounds. We have developed a set of in vitro assays (complimented by our colleagues in the in silico and in vivo areas) that will provide us an our collaborators at the EPA with a rapid understanding of which groups of PFAS are targeting tissues known to be affected by the legacy compounds before them that are no longer produced in the U.S. We are testing nearly 50 of the most common compounds in liver, mammary cells, placenta, fat cells, and kidney to determine bench mark doses across the group. We are also making mixtures for testing in vitro and in vivo from the mass spec data supplied by our EPA collaborators. Our data is needed by the state of NC and the Dept of Defense in the near future to make decisions on new product use, regulation or filtering of water supplies, and potentially health advisories. We will be very busy in this area in the coming years. One manuscript investigating the relationship of chronic disease in human populations with PFAS exposures was recently published this year, with Kelly Ferguson as the senior investigator as she heavily contributed to training my graduate student in the statistical methods needed to determine those exposure-health relationships.
我们的研究重点是了解环境化学物质对乳腺(MG)发育,功能和癌症易感性的影响。近年来,我们扩大了这一重点领域,包括环境化学物质对乳腺癌风险因素的影响,如青春期时间、肥胖和哺乳期。使用动物模型研究人类疾病使我们能够评估不同的接触途径、试验化学品的内部剂量,以及对啮齿动物产生的与人类健康有关的各种影响。在过去几年中,我们制定了许多重要文件,用于溴化阻燃剂(DE-71)、全氟辛酸(PFOA)和阿特拉津(ATR)的风险监管。由于联邦风险评估尚未完成,阻燃剂目前在州一级受到监管。大鼠DE-71的研究目前已经完成,但近年来我们扩大了对阻燃剂的研究,包括四溴双酚A (TBBPA)和Firemaster 550。我继续建议国家毒理学规划正在进行的关于这些高用途和新兴阻燃剂作用机制的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Suzanne Fenton其他文献

Suzanne Fenton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Suzanne Fenton', 18)}}的其他基金

Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    8336657
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    8553801
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    8734165
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Emerging Contaminants and Issues of Concern Research Program
新出现的污染物和关注问题研究计划
  • 批准号:
    10914584
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    10259348
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Emerging Contaminants and Issues of Concern Research Program
新出现的污染物和关注问题研究计划
  • 批准号:
    10696800
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    8929805
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    8149121
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
乳腺作为内分泌干扰物影响的敏感终点
  • 批准号:
    9354102
  • 财政年份:
  • 资助金额:
    $ 330.09万
  • 项目类别:

相似国自然基金

相似海外基金

New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
  • 批准号:
    23K16058
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
  • 批准号:
    23K10969
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
  • 批准号:
    10751284
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
  • 批准号:
    23H03065
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
  • 批准号:
    23K05107
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
  • 批准号:
    23K19518
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
  • 批准号:
    23K18303
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
  • 批准号:
    10655793
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
  • 批准号:
    23K05594
  • 财政年份:
    2023
  • 资助金额:
    $ 330.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Characterizing breast cancer invasion and proliferation when co-aggregated with adipocytes in multicellular spheroids created with a custom bioreactor to augment cell-cell connectivity.
当与多细胞球体中的脂肪细胞共聚集时,表征乳腺癌的侵袭和增殖,该多细胞球体是用定制生物反应器创建的,以增强细胞间的连接。
  • 批准号:
    10334113
  • 财政年份:
    2022
  • 资助金额:
    $ 330.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了